ARS Pharmaceuticals, Inc. Increase (Decrease) in Due to Related Parties
ARS Pharmaceuticals, Inc. (SPRY) reported Increase (Decrease) in Due to Related Parties of $478.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2025-03-20
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for the quarter ending 2024-12-31 was $523.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for the quarter ending 2024-09-30 was $11.00K, a 71.05% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for the quarter ending 2024-06-30 was -$158.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for the quarter ending 2024-03-31 was $102.00K, a 64.95% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for fiscal 2024 was $478.00K, a 195.06% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for fiscal 2023 was $162.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for fiscal 2022 was -$143.00K, a 1200.00% decline from fiscal 2021.
- ARS Pharmaceuticals, Inc. increase (decrease) in due to related parties for fiscal 2021 was $13.00K.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2024-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $534.00K derived: sum of 2 quarters · filed 2025-03-20 | $376.00K derived: sum of 3 quarters · filed 2025-03-20 | $478.00K 10-K · filed 2025-03-20 |
| 2024-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$147.00K derived: sum of 2 quarters · filed 2024-11-13 | -$45.00K 10-Q · filed 2024-11-13 | -$75.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | -$158.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$56.00K 10-Q · filed 2024-08-06 | -$86.00K derived: sum of 3 quarters · filed 2025-03-20 | -$48.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $102.00K 10-Q · filed 2024-05-09 | $72.00K derived: sum of 2 quarters · filed 2025-03-20 | $110.00K derived: sum of 3 quarters · filed 2025-03-20 | -$27.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $8.00K derived: sum of 2 quarters · filed 2025-03-20 | -$129.00K derived: sum of 3 quarters · filed 2025-03-20 | $162.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$99.00K derived: sum of 2 quarters · filed 2024-11-13 | $192.00K 10-Q · filed 2024-11-13 | -$171.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $154.00K 10-Q · filed 2024-08-06 | -$209.00K derived: sum of 3 quarters · filed 2024-08-06 | -$189.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $291.00K 10-Q · filed 2024-05-09 | -$72.00K derived: sum of 2 quarters · filed 2024-05-09 | -$52.00K derived: sum of 3 quarters · filed 2024-05-09 | $93.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$343.00K derived: sum of 2 quarters · filed 2024-03-21 | -$198.00K derived: sum of 3 quarters · filed 2024-03-21 | -$143.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $165.00K derived: sum of 2 quarters · filed 2023-11-09 | $220.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $200.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $55.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $13.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |